OLMA stock forecast, quote, news & analysis

Key Takeaways

• OLMA shares have declined roughly 26% over the last 30 days, with the latest closing price near $7.25 versus about $9.82 at the start of the period.
• The pullback extends a longer slide, with the stock down approximately 36% over the trailing three-month period.
• Investor caution is centered on the company's pivotal OPERA-01 Phase 3 data readout for palazestrant, expected in the fall, a binary catalyst for a pre-revenue biotech.
• Rising research and development spending and continued cash burn have amplified sensitivity to the pending clinical milestones.
• Analyst price targets remain above the current share price, but recent insider selling has weighed on sentiment.

Olema Pharmaceuticals (OLMA) Company Overview and Market Position

Olema Pharmaceuticals, Inc., which operates as Olema Oncology, is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and other women's cancers. Headquartered in San Francisco with operations in Cambridge, Massachusetts, the company leverages its expertise in endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.

Its lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being studied in two Phase 3 trials: OPERA-01 as a monotherapy, and OPERA-02 in combination with ribociclib in the frontline metastatic setting. Palazestrant holds U.S. FDA Fast Track designation for ER+/HER2- metastatic breast cancer. Olema is also advancing OP-3136, a KAT6 inhibitor in Phase 1 development. Because the company has no marketed products or revenue, investors track the stock primarily for clinical trial progress, regulatory milestones, and its cash position, which totaled approximately $505.3 million as of March 31, 2026.

Olema Pharmaceuticals (OLMA) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, OLMA has fallen roughly 26%, declining from a closing price near $9.82 to approximately $7.25. The move was largely a steady grind lower punctuated by sharp down days, with the stock reaching a recent low near $6.58 in mid-October before a modest rebound.

The quarterly picture is similarly weak. From a closing level near $11.35 in mid-July, the shares have dropped approximately 36%, extending a broader downtrend that began earlier in the year. The decline has not been driven by a single catastrophic event but by sustained selling pressure across a multi-month period, reflecting waning risk appetite for a clinical-stage oncology name approaching a major binary data readout.

What Drove OLMA Stock Price in the Last 30 Days

The 30-day decline has been shaped by several overlapping factors rather than one isolated catalyst. Most importantly, Olema is approaching a pivotal moment: top-line data from the Phase 3 OPERA-01 trial of palazestrant as a monotherapy is expected during the fall. In the run-up to a binary readout of this nature, pre-revenue biotech stocks often experience de-risking and position trimming, as investors reassess the risk-reward ahead of an outcome that can meaningfully swing valuation in either direction.

Sentiment has also been pressured by the company's rising spending. First-quarter 2026 results showed a net loss of $53.1 million, up from $30.4 million a year earlier, driven by higher research and development expenses tied to late-stage palazestrant trials and the advancement of OP-3136. Although Olema maintains a substantial cash balance, continued cash burn heightens sensitivity to the timing and outcome of its clinical milestones.

Additional pressure has come from reported insider selling activity. Filings indicated that a board member, Cyrus Harmon, sold 25,000 shares in the recent period, and broader insider sentiment has been described as negative. Meanwhile, analyst coverage has remained constructive, with firms including Piper Sandler and LifeSci Capital maintaining Buy ratings and price targets well above the current price, yet that has not been enough to offset the cautious positioning ahead of the data readout.

What Drove OLMA Stock Performance Over the Last Quarter

The roughly 36% decline over the trailing three months reflects a larger narrative of repricing in Olema's shares. In August, the company reported second-quarter 2026 financial results, and the stock sold off sharply in the following session as investors digested elevated spending and the company's continued path toward late-stage trials without near-term revenue.

Beyond quarterly results, the multi-month trend has been shaped by the market's growing focus on execution risk. Olema is a clinical-stage company with a relatively new management team, heavy cash burn, and no product revenue, all of which become more prominent concerns as a binary trial readout approaches. Sector-wide pressure on small-cap and clinical-stage biotech names, combined with competition in the SERD space, has compounded the stock's weakness and kept buyers on the sidelines through much of the period.

Trending AI Robots

For traders seeking data-driven signals rather than manual analysis, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section, helping users cut through the noise. These bots vary widely in strategy, timeframe, and performance metrics, allowing investors to explore approaches aligned with different risk profiles and market conditions. Browsing the selection can offer a useful, objective complement to traditional research for those interested in systematic, technology-driven market analysis.

OLMA Stock Forecast Drivers: What Investors Should Watch Next

The dominant event on Olema's calendar is the top-line readout from the Phase 3 OPERA-01 trial of palazestrant, expected in the fall. That result will be the primary determinant of near-term share direction, given its implications for a potential regulatory filing and the company's first anticipated commercial launch. Investors should also monitor continued enrollment progress in OPERA-02 and updates on the OP-3136 Phase 1 program.

Other factors to watch include quarterly financial results and the trajectory of research and development spending, any further insider transactions, and changes in analyst estimates or price targets. Competitive developments in the SERD category, broader biotech sector sentiment, and macroeconomic conditions affecting risk appetite for pre-revenue companies will also influence the stock. As with all clinical-stage investments, outcomes remain uncertain and subject to substantial risk.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations